Epidermal growth factor receptor (EGFR) exon 20 mutations in EGFR-tyrosine kinase inhibitors (EGFR-TKIs) naive non-small cell lung carcinoma (NSCLC) and response to erlotinib therapy

被引：1
|
作者：
Aydiner, Adnan [1 ]
Sari, Murat [1 ]
机构：
[1] Istanbul Univ, Inst Oncol, Istanbul, Turkey
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e21212
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21212
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [21] Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib
    Masood, Ashiq
    Kancha, Rama Krishna
    Subramanian, Janakiraman
    SEMINARS IN ONCOLOGY, 2019, 46 (03) : 271 - 283
  • [22] Molecular predictors for epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): role of egfr gene amplification
    Cappuzzo, Federico
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S156 - S157
  • [23] Predicting significance of EGFR mutation existing in tissues and plasma concuurrently or alone to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) for advanced non-small cell lung cancer.
    Wang, Yuyan
    Wang, Jie
    Bai, Hua
    Wang, Zhijie
    Duan, Jianchun
    An, Tongtong
    Zhao, Jun
    Zhuo, Minglei
    Wu, Meina
    Wang, Shuhang
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] Impact of EGFR-Tyrosine Kinase Inhibitors for Postoperative Recurrent Non-Small Cell Lung Cancer Harboring EGFR Mutations
    Igawa, S.
    Sato, Y.
    Kusuhara, S.
    Harada, S.
    Shirasawa, M.
    Kurahayashi, S.
    Okuma, Y.
    Sugimoto, A.
    Sugita, K.
    Nakahara, Y.
    Otani, S.
    Fukui, T.
    Yokoba, M.
    Mitsufuji, H.
    Kubota, M.
    Katagiri, M.
    Sasaki, J.
    Masuda, N.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2126 - S2127
  • [25] Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers
    Fukui T.
    Mitsudomi T.
    General Thoracic and Cardiovascular Surgery, 2008, 56 (3) : 97 - 103
  • [26] The mutation status of the epidermal growth factor receptor (EGFR) as a selection criterion for therapy with EGFR tyrosine kinase inhibitors (TKI's) in non-small cell lung cancer (NSCLC).
    Mathy, A.
    Nederlof, P.
    Boerrigter, L.
    Van 't Veer, L.
    De Jong, D.
    Baas, P.
    Burgers, S.
    Van Zandwijk, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 558S - 558S
  • [27] Tyrosine Kinase Inhibitors and Epidermal Growth Factor Receptor (EGFR) Mutations in Non-Small Cell Lung Cancer To Test or Not to Test?
    Gazdar, Adi F.
    MEDICINE, 2011, 90 (03) : 168 - 170
  • [28] Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
    Gelatti, Ana C. Z.
    Drilon, Alexander
    Santini, Fernando C.
    LUNG CANCER, 2019, 137 : 113 - 122
  • [29] Uncommon epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer and sensitivity to EGFR tyrosine kinase inhibitors, a two centers experience
    Bonomi, M.
    Bonomi, L.
    Sauta, M. G.
    Bettini, A. C.
    Squadroni, M.
    Brena, F.
    Cerchiaro, E.
    Ripa, C.
    Salvini, P.
    Beretta, G. D.
    Tondini, C.
    Ceresoli, G. L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [30] A retrospective analysis of patients (pts) with non-small-cell lung cancer (NSCLC) with uncommon or complex epidermal growth factor receptor (EGFR) mutations treated with tyrosine kinase inhibitors (EGFR-TKIs): clinical features and outcome
    Stasi, I.
    Farnesi, A.
    Vasile, E.
    Petrini, I.
    Luccchesi, M.
    Lupi, C.
    Sensi, E.
    Giannini, R.
    Fornaro, L.
    Caparello, C.
    Pasquini, G.
    Puppo, G.
    Finale, C.
    Barletta, M.
    Chella, A.
    Allegrini, G.
    Falcone, A.
    Fontanini, G.
    ANNALS OF ONCOLOGY, 2017, 28
12345